ROSEN, a leading law firm, promotes functional medicine, Inc. Investors are encouraged to wait for advice before the necessary time frame in a Securities Division action.

NEW YORK, NY–(The News File Corporation – January 13, 2025) – why: Rosen Law Firm, a global investor rights law firm, will appoint App Therapeutics, Inc. (NASDAQ: NASDAQ: ) between January 3, 2024 and December 2, 2024, both dates (the “Class Period”), the relevant February 18, 2025 Lead Plaintiff Deadline.

So what? If you purchase Applied Therapeutics securities during the class period, you may receive reimbursement through a contingency payment arrangement without paying any out-of-pocket fees or expenses.

What to do next: To join the Applied Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=32500 or call Phillip Kim, Esq. Toll free at 866-767-3653 or email case@rosenlegal.com for class action information. A class action lawsuit has already been filed. If you want to serve as lead plaintiff, you must move the court After February 18, 2025. A lead plaintiff is a representative party who conducts litigation on behalf of other class members.

Why the Rose Rule? We encourage investors to select a qualified advisor with a track record of success in a leadership role. Oftentimes, the organizations that issue the ads don’t have comparable experience, resources, or any meaningful peer recognition. Most of these firms do not litigate securities class actions but are intermediaries who refer clients or litigate cases with law firms. Be wise when choosing advice. The Rosen Law Firm represents investors worldwide, focusing its practice on securities class actions and shareholder derivative litigation. Rosen Law Firm brought the largest securities class action against a Chinese company at the time. Rosen Law Firm is rated Class 1 by ISS Securities. Action (WA:) Services in 2017 for the securities division of the action settlement number. The firm has been ranked in the top 4 every year since 2013 and has returned hundreds of millions of dollars to investors. In the year In 2019 alone, the company raised over $438 million for investors. In the year In 2020, founding partner Lawrence Rosen was named a Titan of the Plaintiffs Bar by Law360. Many of the firm’s lawyers are accredited by Laudragon and Super Lawyers.

Details of the case:- According to the lawsuit, the statements made during the class were false and/or materially misleading because Applied Therapeutics concealed and misrepresented its clinical trial protocols and procedures. Consequently, defendants gave investors the false impression that protocol and good clinical practices were being properly followed. The lawsuit alleges that, in fact, Functional Therapeutics is not following trial protocols and good clinical practices, creating a significant risk that the trial data will be rejected by the US Food and Drug Administration (“FDA”). Context of new drug application. The lawsuit alleges that investors were harmed when the real listings entered the market.

To join the Applied Therapeutics class action, call https://rosenlegal.com/submit-form/?case_id=32500 Phillip Kim, Esq. Toll free at 866-767-3653 or email case@rosenlegal.com for class action information.

No class confirmed. Unless a unit is confirmed, you will not be represented by a consultant unless you have booked one. You can choose the advice of your choice. You can also remain a member of a class you are not in and do nothing at this point. An investor’s ability to participate in any future recovery is not dependent on serving as the lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ): https://www.linkedin. com/company/ /www.facebook.com/rosenlawfirm.

Notice of attorney. Previous results do not guarantee the same result.

————————————-

To view the source of this press release, please visit https://www.newsfilecorp.com/release/237072.